Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$5.66 - $7.59 $71,536 - $95,930
-12,639 Reduced 20.83%
48,052 $310,000
Q1 2023

May 15, 2023

BUY
$7.31 - $11.18 $241,624 - $369,543
33,054 Added 119.6%
60,691 $457,000
Q4 2022

Feb 14, 2023

BUY
$9.48 - $14.52 $49,144 - $75,271
5,184 Added 23.09%
27,637 $279,000
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $206,567 - $307,157
22,453 New
22,453 $222,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $807M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.